• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on biological therapy >Pegfilgrastim for the prevention of chemotherapy-induced febrile neutropenia in patients with solid tumors
【24h】

Pegfilgrastim for the prevention of chemotherapy-induced febrile neutropenia in patients with solid tumors

机译：Pegfilgrastim预防实体瘤患者化疗引起的发热性中性粒细胞减少

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Introduction: Neutropenia and febrile neutropenia are the most common and most severe bone marrow toxicities of chemotherapy. Recombinant granulocyte-colony stimulating factors (G-CSFs), both daily (filgrastim and biosimilars, and lenograstim) and long-acting (pegfilgrastim and lipegfilgrastim) formulations, are currently available to counteract the negative consequences of these side effects.Areas covered: The purpose of this article is to review the physiopathology of chemotherapy-induced febrile neutropenia and its consequences, and the current evidence regarding the pharmacological properties, clinical efficacy and cost-effectiveness of pegfilgrastim as a strategy to prevent chemotherapy-induced febrile neutropenia in patients with solid tumors.Expert opinion: Chemotherapy-induced febrile neutropenia and its complications are still a major health-care concern, and the inappropriate employment of G-CSFs in clinical practice can partially explain its burden. Pegfilgrastim has pharmacological advantages over daily G-CSFs that makes it easily administrable, thus reducing the chance of incorrect delivery. The once-per-cycle administration might explain the findings derived from observational studies suggesting a possible superior efficacy of pegfilgrastim over daily G-CSFs. For patients at higher risk of failure with daily G-CSF prophylaxis (e.g. risk of non-compliance, difficulties on performing regular hemograms, high risk of developing febrile neutropenia), pegfilgrastim might be the most appropriate option.
机译：简介：中性粒细胞减少和发热性中性粒细胞减少是化学疗法最常见和最严重的骨髓毒性。重组的粒细胞集落刺激因子（G-CSFs）既可以每日使用（非格司亭和生物仿制药，也可以使用lenograstim）和长效（pegfilgrastim和lipegfilgrastim）制剂来抵消这些副作用的负面影响。本文的目的是回顾化学疗法诱导的发热性中性粒细胞减少症的生理病理学及其后果，以及有关聚乙二醇非格司亭作为预防固体综合征患者化学疗法诱发的发热性中性粒细胞减少症的策略的当前证据专家意见：化疗引起的发热性中性粒细胞减少症及其并发症仍然是医疗保健方面的主要问题，临床实践中不适当使用G-CSF可以部分解释其负担。培格非司亭与每日G-CSF相比具有药理学优势，使其易于管理，从而减少了错误分娩的机会。每个周期一次的给药可能解释了观察性研究的结果，表明培格非司亭比每日G-CSF可能具有更好的疗效。对于每天预防G-CSF失败风险较高的患者（例如，不依从风险，进行常规血栓检查有困难，发生发热性中性粒细胞减少症的高风险），培非非司亭可能是最合适的选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号